PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

First-in-human study of once-daily oral treatment for obesity that mimics metabolic effects of gastric bypass without surgery

SYNT-101 offers a novel approach to weight loss by temporarily redirecting nutrient absorption in the small intestine

2025-05-13
(Press-News.org) A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrated positive preliminary data for the safe and effective redirection of nutrient absorption into the lower intestine, the weight loss and metabolic management mechanism behind gastric bypass surgery.

In the study, being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), participants were surveyed for adverse events, tolerability markers, as well as modulation of satiety hormones that influence hunger and weight loss. The results suggest a strong safety and tolerability profile, along with control of hunger and weight loss.

“These data validate the potential of SYNT-101 to induce metabolic changes that support glycaemic control, weight loss and energy balance,” said Rahul Dhanda, chief executive officer of Syntis Bio, the Boston-based biopharmaceutical company developing SYNT-101.

“We believe that SYNT-101 will provide a convenient, more sustainable oral alternative and/or complement to systemic therapies such as GLP-1 drugs. The millions of people living with obesity need novel treatment options that are safe, effective and avoid the high costs and severe side effects that often accompany available treatment options.” 

Many obesity medications, like GLP-1 receptor agonists, are effective in aiding weight loss, but loss of lean muscle remains a common concern. There are also ongoing issues with these drugs around accessibility, gastrointestinal side effects and long-term maintenance.

SYNT-101 mimics the effects of gastric bypass by forming a temporary polydopamine coating in the duodenum, shifting nutrient exposure to the lower intestine to naturally promote satiety and support metabolic balance.

In addition, this “duodenal nutrient exclusion” effect improves satiety and metabolic regulation, and has been shown to better preserve lean muscle mass compared to GLP-1 drugs. The polydopamine lining is designed work for up to 24 hours, after which it is naturally cleared from the body. SYNT-101 will ultimately be delivered in a once-daily oral pill.

In preclinical studies, SYNT-101 has shown promising effects on glycaemic control and produced weight loss of 1% a week for six weeks while preserving 100% of lean muscle mass in rodent models.

In the human pilot study, nine healthy participants (2 male, 7 female, aged 24–53 years, BMI 19–29 kg/m2), received a single dose of SYNT-101 in liquid form, administered in three dose levels. Two participants were given 25% of the target dose, three received 50% and four received the full target dose.

Researchers conducted safety assessments and oral glucose tolerance tests to evaluate the tolerability and efficacy of SYNT-101, as well as endoscopic imaging to check whether the upper part of the small intestine was fully coated with the temporary polydopamine lining.

Blood tests were also conducted before and after treatment with SYNT-101 to assess the effects on satiety and metabolic hormone levels, including liver enzymes, leptin (a hormone that regulates appetite) and ghrelin (a hormone that causes hunger).

Endoscopic imaging confirmed that the polymer coating formed as expected across the upper small intestine, and tissue samples showed that SYNT-101 was safely eliminated within 24 hours of administration. No adverse or serious adverse events were reported in any dosage group.

During the 10 days following treatment, liver enzymes including aspartate transaminase (AST), alanine transaminase (ALT) and bilirubin remained stable for each participant, consistent with normal liver functioning.

Additionally, gastrointestinal tolerance was excellent, with no changes noted in the Gastrointestinal Symptom Rating Scale (GSRS), and all participants reported an average pain rating of 0.

Importantly, glucose tolerance tests revealed delayed uptake of glucose following SYNT-101 treatment. At 30 and 60 minutes, glucose absorption was far lower than in untreated patients, by roughly 35% and 21% respectively. This delay suggests that absorption occurs later in the intestine, as expected, rather than in the coated region of the duodenum.

Although the pilot study was not designed to measure weight loss, participants receiving a full dose of SYNT-101 also received blood tests, which showed elevated levels of leptin and lower levels of ghrelin, consistent with findings from preclinical in vivo models showing reduced food intake.

The authors note that larger trials are needed to fully assess the drug's efficacy and safety. Syntis Bio plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) during the second half of 2025.

Dhanda added, “We are eager to replicate these data in our upcoming Phase 1 clinical trial and further explore the ability of SYNT-101 to produce sustainable, safe, effective weight loss by reducing fat, preserving lean muscle and stimulating natural production of satiety hormones to prevent weight regain.”

For interviews with article authors, please email Dan Budwick, 1AB, USA at dan@1abmedia.com

Alternative contact in the ECO Press Room: Tony Kirby T) + 44(0)7834 385827 E) tony@tonykirby.com

Notes to editors:

The authors declare no conflicts of interest.

This press release is based on poster abstract 1297 at the European Congress on Obesity (ECO). All accepted abstracts have been extensively peer reviewed by the congress selection committee. There is no full paper at this stage, but the authors are happy to answer your questions. The research has not yet been submitted to a medical journal for publication. 

For full abstract

For full poster click here

 

END


ELSE PRESS RELEASES FROM THIS DATE:

Rural preschoolers more likely to be living with overweight and abdominal obesity, and spend more time on screens, than their urban counterparts

2025-05-13
New research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals that 3- to 4- year olds in rural areas are more likely to be living with overweight and abdominal obesity (excess fat around waist), and spend more time on screens than their urban counterparts.  “Our findings reveal distinct patterns of how physical activity, screen time, and sleep relate to overweight and abdominal obesity in urban and rural settings, indicating that one-size-fits-all strategies to tackle ...

Half of popular TikToks about “food noise” mention medications, mainly weight-loss drugs, to manage intrusive thoughts about food

2025-05-13
A new analysis being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), finds that around half of the 100 top TikTok videos about food noise reference the use of medications—mainly the popular anti-obesity drugs glucagon-like peptide-1 receptor agonists (GLP-1RAs)—to manage constant and persistent thoughts about food and eating.  “TikTok can be an incredible tool for raising awareness, but it also has a downside,” said lead author Daisuke Hayashi from the Pennsylvania State University, USA. “The ...

Global survey reveals high disconnect between perceptions of obesity among people living with the disease and their doctors

2025-05-13
A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their perceptions about the causes of obesity and treatment goals. The findings being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), highlight biased misconceptions about obesity which may impact patients’ access to treatment and support. “Although the causes of weight gain and obesity are diverse and complex—and often beyond an ...

Study reveals distinct mechanisms of action of tirzepatide and semaglutide

2025-05-13
New animal research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment, with tirzepatide temporarily increasing energy expenditure and semaglutide initially reducing energy expenditure. Importantly, the biggest metabolic changes happen directly after treatment and disappear quickly after treatment is stopped. Anti-obesity drugs like tirzepatide and semaglutide have shown substantial promise in promoting weight loss and improving metabolic ...

Mount Sinai Health System to honor Dennis S. Charney, MD, Dean of the Icahn School of Medicine at Mount Sinai, for 18 years of leadership and service at annual Crystal Party  

2025-05-13
New York, NY (May 13, 2025) – Mount Sinai Health System announced today that it will recognize Dennis S. Charney, MD, the outgoing Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, for 18 years of leadership and service at its 40th annual Crystal Party, Tuesday, May 20, at Pier Sixty, 60 Chelsea Piers. Dr. Charney is one of the longest-serving deans of any medical school nationwide and will step down as Dean on Monday, June 30. He will remain on the faculty at the Icahn School of Medicine at Mount ...

Mapping a new brain network for naming

2025-05-13
How are we able to recall a word we want to say? This basic ability, called word retrieval, is often compromised in patients with brain damage. Interestingly, many patients who can name words they see, like identifying a pet in the room as a “cat”, struggle with retrieving words in everyday discourse. Scientists have long sought to understand how the brain retrieves words during speech. A new study by researchers at New York University sheds light on this mystery, revealing a left-lateralized network in the dorsolateral prefrontal cortex that plays a crucial role in naming. The findings, published in Cell Reports, provide new insights into ...

Healthcare company Watkins-Conti announces publication of positive clinical trial results for FDA-cleared Yōni.Fit bladder support

2025-05-13
EDMOND, Okla. – May 13, 2025 -- Watkins-Conti Products, Inc. ("Watkins-Conti"), a company that develops innovative solutions for women's pelvic health, today announced the peer-reviewed publication of clinical trial results evaluating Yōni.Fit® Bladder Support ("Yōni.Fit®"). Designed and manufactured in the United States, Yōni.Fit® obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) in 2024 for the temporary management of urine ...

Prominent chatbots routinely exaggerate science findings, study shows

2025-05-13
When summarizing scientific studies, large language models (LLMs) like ChatGPT and DeepSeek produce inaccurate conclusions in up to 73% of cases, according to a new study by Uwe Peters (Utrecht University) and Benjamin Chin-Yee (Western University, Canada/University of Cambridge, UK). The researchers tested the most prominent LLMs and analyzed thousands of chatbot-generated science summaries, revealing that most models consistently produced broader conclusions than those in the summarized texts. Surprisingly, prompts ...

First-ever long read datasets added to two Kids First studies

2025-05-13
This new Kids First data creates a fuller understanding of how genetics contributes to childhood cancers and congenital disorders, opening additional doors for prevention and treatment.  WHO: The Gabriella Miller Kids First Pediatric Research Program (Kids First), an initiative of the National Institutes of Health (NIH). Kids First data, tools, and resources are available via the Kids First Data Resource Center (DRC). WHAT: The 2025 releases represent the first batch of long read sequencing data ...

Dual-laser technique lowers Brillouin sensing frequency to 200 MHz

2025-05-13
Scientists have developed a dual-laser Brillouin optical correlation-domain reflectometry (BOCDR) system that uses two frequency-modulated lasers. By scanning the relative modulation phase between the pump and reference lasers, the setup measures strain and temperature all along an optical fiber. In a proof-of-concept test on a 13-meter silica fiber, the team recorded Brillouin gain spectra (BGS) at only about 200 MHz—over 50 times lower than the usual 11 GHz band. Their research was published in Journal of Physics: Photonics on April 25, 2025. “The dual-laser approach makes BOCDR equipment simpler, more cost-effective, ...

LAST 30 PRESS RELEASES:

New way to find “aged” cells marks fresh approach for research into ageing

From blood sugar to brain relief: GLP-1 therapy slashes migraine frequency

Variability in heart rate during sleep may reveal early signs of stroke, depression or cognitive dysfunction, new study shows

New method to study catalysts could lead to better batteries

Current Molecular Pharmacology impact factor rises to 2.9, achieving Q2 ranking in the Pharmacology & Pharmacy category in 2024 JCR

More time with loved ones for cancer patients spared radiation treatment

New methods speed diagnosis of rare genetic disease

Genetics of cardiomyopathy risk in cancer survivors differ by age of onset

Autism inpatient collection releases genetic, phenotypic data for more than 1,500 children with autism

Targeting fusion protein’s role in childhood leukemia produces striking results

Clear understanding of social connections propels strivers up the social ladder

New research reveals why acute and chronic pain are so different – and what might make pain last

Stable cooling fostered life, rapid warming brought death: scientists use high-resolution fusuline data reveal evolutionary responses to cooling and warming

New research casts doubt on ancient drying of northern Africa’s climate

Study identifies umbilical cord blood biomarkers of early onset sepsis in preterm newborns

AI development: seeking consistency in logical structures

Want better sleep for your tween? Start with their screens

Cancer burden in neighborhoods with greater racial diversity and environmental burden

Alzheimer disease in breast cancer survivors

New method revolutionizes beta-blocker production process

Mechanism behind life-threatening cancer drug side-effect revealed

Weighted vests might help older adults meet weight loss goals, but solution for corresponding bone loss still elusive

Scientists find new way to predict how bowel cancer drugs will stop working – paving the way for smarter treatments

Breast cancer patients’ microbiome may hold key to avoiding damaging heart side-effects of cancer therapies

Exercise-induced protein revives aging muscles and bones

American College of Cardiology issues guidance on weight management drugs

Understanding the effect of bedding on thermal insulation during sleep

Cosmic signal from the very early universe will help astronomers detect the first stars

With AI, researchers find increasing immune evasion in H5N1

Study finds hidden effects of wildfires on water systems

[Press-News.org] First-in-human study of once-daily oral treatment for obesity that mimics metabolic effects of gastric bypass without surgery
SYNT-101 offers a novel approach to weight loss by temporarily redirecting nutrient absorption in the small intestine